Affinivax is a biotechnology start-up built around a streamlined, low-cost vaccine platform system. The company's goal is to develop a pipeline of vaccines that provide broader protective coverage than existing vaccines or that protect against infectious diseases for which there are currently no effective vaccines.
Boston Children's Hospital licensed the intellectual property for the system, known as the Multiple Antigen Presenting System (MAPS), to Affinivax from the laboratory of Richard Malley, MD, an infectious diseases specialist and senior physician in medicine at Boston Children's.
Affinivax, which secured $4 million in initial funding from the Bill & Melinda Gates Foundation in 2014, is first focused on using the technology to create a new vaccine for Streptococcus pneumonia (pneumococcus), a leading cause of death among children under five in the developing world. Affinivax may extend MAPS to vaccines for other diseases in the future.
Key research partners
News and highlights